- Home
- WATT vs APRE Comparison
WATT vs APRE Comparison
Compare WATT & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- APRE
- Stock Information
- Founded
- WATT 2012
- APRE 2006
- Country
- WATT United States
- APRE United States
- Employees
- WATT N/A
- APRE N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WATT Technology
- APRE Health Care
- Exchange
- WATT Nasdaq
- APRE Nasdaq
- Market Cap
- WATT 9.1M
- APRE 9.7M
- IPO Year
- WATT 2014
- APRE 2019
- Fundamental
- Price
- WATT $0.28
- APRE $1.74
- Analyst Decision
- WATT
- APRE Strong Buy
- Analyst Count
- WATT 0
- APRE 2
- Target Price
- WATT N/A
- APRE $15.50
- AVG Volume (30 Days)
- WATT 2.0M
- APRE 30.7K
- Earning Date
- WATT 05-13-2025
- APRE 05-14-2025
- Dividend Yield
- WATT N/A
- APRE N/A
- EPS Growth
- WATT N/A
- APRE N/A
- EPS
- WATT N/A
- APRE N/A
- Revenue
- WATT $1,047,000.00
- APRE $1,284,475.00
- Revenue This Year
- WATT $1,028.91
- APRE N/A
- Revenue Next Year
- WATT N/A
- APRE N/A
- P/E Ratio
- WATT N/A
- APRE N/A
- Revenue Growth
- WATT 137.41
- APRE 33.27
- 52 Week Low
- WATT $0.12
- APRE $1.41
- 52 Week High
- WATT $2.70
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- WATT 50.45
- APRE 50.55
- Support Level
- WATT $0.27
- APRE $1.60
- Resistance Level
- WATT $0.29
- APRE $1.97
- Average True Range (ATR)
- WATT 0.02
- APRE 0.18
- MACD
- WATT 0.00
- APRE 0.02
- Stochastic Oscillator
- WATT 40.25
- APRE 51.79
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.